论文部分内容阅读
恶性肿瘤是危害人体健康的主要疾病之一,寻找治疗恶性肿瘤的药物一直是全世界药物研发的热点。近年来金属配合物作为抗肿瘤药物被大量研究,钌类金属配合物因其结构稳定,光物理化学性质丰富,生物应用性能良好,具有低毒、易吸收、易排泄、易修饰和易示踪等优点受到广泛重视。本文以钌类金属配合物的结构为主要脉络,其抗肿瘤机制为次要分类,总结评述了近年来钌类金属抗肿瘤化合物的研究进展,并对其在配合物结构、抗癌机理以及在药理、药物动力学和临床等方面进一步研究的前景进行了展望。
Malignant tumors are one of the major diseases endangering human health. Finding drugs to treat malignant tumors has been a hot spot in drug development in the world. In recent years, metal complexes have been extensively studied as anti-tumor drugs. Because of their structural stability, ruthenium metal complexes are rich in physico-chemical properties and have good biological application properties, they are low in toxicity, easily absorbed, easily excreted, easily modifiable and easy to be traced Advantages such as widespread attention. In this paper, the structure of ruthenium metal complexes as the main context, its anti-tumor mechanism as a secondary classification, summarizes the recent research progress of ruthenium metal anti-tumor compounds, and its structure in the complex, anticancer mechanism and in Pharmacology, pharmacokinetics and clinical aspects of the prospects for further research.